The Latest Breaking News from HIV

The pioneering African country is lauded for slashing rates of mother-to-child transmission to just 1.2% and is holding trials that may now hold the key to curing young people

CVS Health Inc. (NYSE:CVS) said it will not add Gilead Sciences Inc.’s (NASDAQ:GILD) new HIV prevention drug Yeztugo to its commercial plans.

Globally, an estimated 1.3 million women and girls living with HIV become pregnant every year, according to the World Health Organization

Decisions from the U.S. Preventative Services Task Force impact millions of people’s access to preventative care for cancer, infectious diseases and mental health

In June, the U.S. Food and Drug Administration (FDA) approved Gilead Sciences, Inc.'s (NASDAQ:GILD) Yeztugo (lenacapavir) as pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV in adults and adolescents weighing at least 35kg, making it the first and only twice-yearly option available in the U.S. for people who need or…

The European Medicines Agency has recommended authorizing a twice-yearly injectable drug to prevent HIV

The drug is expected to be formally approved by the European Commission this year.

My phone wouldn’t stop ringing – nurses, social workers, young mothers – all begging for help. ‘I’ve lost my job,’ ‘I have no food,’ ‘What do we do now?’ I felt helpless.

The US Senate votes to keep money for the President’s Emergency Plan for Aids Relief from a package of more than $9 billion in cuts going through Congress